WLLW — Willow Biosciences Income Statement
0.000.00%
Last trade - 00:00
- CA$13.42m
- CA$13.81m
- CA$1.17m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.005 | 0.01 | 0.133 | 0.821 | 1.17 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 46.2 | 34 | 23.5 | 19.6 | 14.4 |
Operating Profit | -46.2 | -33.9 | -23.3 | -18.8 | -13.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -46.1 | -33.9 | -6.14 | -14.8 | -13 |
Provision for Income Taxes | |||||
Net Income After Taxes | -44.6 | -33.9 | -6.14 | -14.8 | -13 |
Net Income Before Extraordinary Items | |||||
Net Income | -44.6 | -33.9 | -6.14 | -14.8 | -13 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -44.6 | -33.9 | -6.14 | -14.8 | -13 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.315 | -0.338 | -0.05 | -0.118 | -0.105 |